| 词条 | Anacetrapib |
| 释义 |
| Verifiedfields = changed | verifiedrevid = 444391072 | ImageFile = Anacetrapib.svg | ImageSize = 200px | IUPACName = (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one | OtherNames = MK-0859 |Section1={{Chembox Identifiers | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 9731205 | InChI = 1/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1 | InChIKey = MZZLGJHLQGUVPN-HAWMADMCBN | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = MZZLGJHLQGUVPN-HAWMADMCSA-N | UNII_Ref = {{fdacite|correct|FDA}} | UNII = P7T269PR6S | CASNo_Ref = {{cascite|correct|??}} | CASNo = 875446-37-0 | PubChem = 11556427 | ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL = 1800807 | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D08855 | SMILES = O=C2O[C@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)[C@@H](N2Cc4c(c3cc(c(F)cc3OC)C(C)C)ccc(c4)C(F)(F)F)C }} |Section2={{Chembox Properties | Formula = C30H25F10NO3 | MolarMass = 637.51 g·mol−1 | Appearance = | Density = | MeltingPt = | BoilingPt = | Solubility = |Section3={{Chembox Hazards | MainHazards = | FlashPt = | AutoignitionPt = }}Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort prevent cardiovascular disease.[1] In 2017 its development was abandoned by Merck.[2] EvidenceIn 2017 REVEAL trial anacetrapib was shown to decrease the risk of repeat heart attacks in high-risk patients with previous acute coronary events.[3] See alsoOther CETP inhibitors:
References1. ^{{cite journal |vauthors =Gutstein DE, Krishna R, Johns D |title=Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction |journal=Clinical Pharmacology & Therapeutics |volume=91 |issue=1 |pages=109–122 |year=2012 |doi=10.1038/clpt.2011.271 |url=http://www.nature.com/clpt/journal/v91/n1/full/clpt2011271a.html| display-authors=etal}} 2. ^{{cite news|title=Merck says will not seek approval of cholesterol treatment|url=https://www.reuters.com/article/us-merck-cholesterol/merck-says-will-not-seek-approval-of-cholesterol-treatment-idUSKBN1CG2W1|accessdate=18 October 2017|work=Reuters|date=2017}} 3. ^{{cite journal|last1=Filippatos|first1=TD|last2=Kei|first2=A|last3=Elisaf|first3=MS|title=Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?|journal=Diseases (Basel, Switzerland)|date=29 September 2017|volume=5|issue=4|doi=10.3390/diseases5040021|pmid=28961179|pmc=5750532|page=21}} Further reading
6 : Trifluoromethyl compounds|Oxazolidinones|O-Methylated phenols|Experimental drugs|Fluoroarenes|Isopropyl compounds |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。